Clinical Trial Update: Sintilimab in Combination With Chidamide in Refractory and Relapsed AITL [Phase 2]

View source ↗

Summary

Phase 2 trial exploring sintilimab in combination with chidamide for refractory and relapsed angioimmunoblastic T-cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angioimmunoblastic T-cell Lymphoma

Drugs mentioned

• Chidamide (chidamide)
• Sintilimab (sintilimab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Angioimmunoblastic T-cell Lymphoma | Phase 2 | Status: UNKNOWN